Place de ta vitamine D, du sevelamer et du cinacalcet dans la prise en charge des patients en insuffisance rénale [Treatment of secondary hyperparathyroidism in renal insufficiency: role of calcitriol, sevelamer and cinacalcet]


Autoria(s): Bonny O.; Burnier M.
Data(s)

2008

Resumo

Along with the decrease in kidney function arises a secondary hyperparathyroidism, which constitutes one of the most important risk factor for mortality in patients suffering from renal insufficiency. Treating secondary hyperparathyroidism is challenging, as most of the parameters of mineral metabolism are interconnected. We review here the pathophysiology and treatment options of this entity.

Identificador

http://serval.unil.ch/?id=serval:BIB_B8FFEE76BE39

isbn:1660-9379[print], 1660-9379[linking]

pmid:18402017

Idioma(s)

fr

Fonte

Revue Médicale Suisse, vol. 4, no. 147, pp. 589-92, 594-5

Palavras-Chave #Calcitriol/therapeutic use; Chelating Agents/therapeutic use; Humans; Hyperparathyroidism, Secondary/drug therapy; Hyperparathyroidism, Secondary/etiology; Naphthalenes/therapeutic use; Polyamines/therapeutic use; Renal Insufficiency/complications; Vitamin D Deficiency/drug therapy; Vitamins/therapeutic use
Tipo

info:eu-repo/semantics/review

article